Wire · opportunities
K-bio fuels melanoma race as FDA speeds Replimune-Opdivo combo approval
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 12 August 2026 · Fusion42 review
The FDA granted accelerated approval for Replimune's Tudurivib combined with Bristol Myers Squibb's Opdivo for advanced melanoma, spurring Korean biotech firms to develop combination therapies targeting melanoma subtypes, with confirmatory trials ongoing to prove clinical benefit.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
US biotech founders in melanoma drug development face a market opportunity as accelerated FDA approval opens the door for new combination therapies. Speed up trials and partnerships now or risk losing ground to Korean firms targeting niche melanoma mutations with complementary therapies.
◆ Coverage
1 source · 11 Aug 2026
◆ Related on Wire
◆ Topics